<DOC>
	<DOCNO>NCT01369563</DOCNO>
	<brief_summary>To assess efficacy , safety tolerability ciclesonide 200 mcg daily , apply nasal spray four week . The main outcome improvement global individual typical associate symptom intermittent persistent rhinitis .</brief_summary>
	<brief_title>Efficacy , Safety &amp; Tolerability Ciclesonide 200mcg Spray 4 Weeks Treatment Intermittent &amp; Persistent Rhinitis</brief_title>
	<detailed_description>Study design : This prospective national wide Non- Interventional study . Patients number 2400 CRFs distribute order obtain ITT ( Intention Treat ) sample 1800 ( 75 % ) patient , PP ( Per Protocol ) sample 1100 patient ( 60 % ) . 400 patient apply `` prick test '' result analyze determine prevalence response treatment accord diagnosis allergic rhinitis . Eligible population Male female external patient 18 year 50 year active rhinitis ( anterior posterior rhinorrhea , sneeze , nasal congestion itch ) persistent ( ≥ 4 day week 4 consecutive week ) intermittent ( &lt; 4 day week ≤ 4 consecutive week ) , medical history rhinitis 2 year prior participation study whose nasal symptom severe enough require continuous intermittent treatment ( require patient 's symptom need treatment least 4 week period ) . All patient sign inform consent give verbal confirmation prior inclusion study . Evaluation criterion : Primary : Symptoms relief intermittent persistent rhinitis . Secondary : Safety profile ( MedDRA adverse event ) , tolerability treatment compliance . Collective evaluation : The PP population consider confirmatory analysis . The key variable `` symptom relief '' assess Intent-to-treat population ITT comparison . Statistical analysis : The investigator perform descriptive analysis demographic data score symptoms severity intermittent persistent rhinitis ( ie , nasal congestion , anterior posterior rhinorrhea , sneeze nasal itch ) . All result express mean value standard deviation , percentages case categorical variable . Symptoms improvement assess use symptom severity score register ( physician patient ) initial visit versus record final visit . The contrast mean adjust recruitment center ( random factor ) , physician ' specialty ( random factor ) , demographic variable age , sex , body mass index ( fix factor case categories covariates case continuous variable ) . The frequency adverse event record case important finding investigator search risk factor use nested sample population match age sex .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>1 . All patient sign inform consent give verbal confirmation prior inclusion study . 2 . Outpatient ( external ) male female 18 year 50 year . 3 . Patients active rhinitis ( anterior posterior rhinorrhea , sneeze , nasal congestion itch ) persistent ( ≥ 4 day week 4 consecutive week ) intermittent ( &lt; 4 day week ≤ 4 consecutive week ) . 4 . Patient medical history rhinitis 2 year prior participation study whose nasal symptom severe enough require continuous intermittent treatment ( require patient 's symptom need treatment least 4 week period ) . 5 . Patient ability understand risk benefit requirement participate study able accomplish study treatment fill questionnaire patient 's diary . 1 . Patient nasal disease include : nasal polyp nasal trauma recent . 2 . Patient intranasal malformation ( cyst fistulas nose dorsum , prenasal space malformation , midline dystrophy , arrhinea , abnormality tear duct ) , condition ; recent nasal biopsy , drug rhinitis . 3 . Noncontrolled asthma systemic corticosteroid treatment . 4 . Patient Chronic Obstructive Pulmonary Disease . 5 . Medical history respiratory infection disease include bronchitis , pneumonia , common cold , acute chronic sinusitis , influenza , etc . within 30 day prior inclusion study . 6 . Patient receive antibiotic therapy acute illness past 14 day . 7 . Patient vaccinate pneumococcus , H1N1 &amp; seasonal influenza ( past 30 day ) . 8 . Patient require initiation dose escalation immunotherapy . Immunotherapy permit start 90 day ago patient receive stable dose last 30 day . 9 . Patient participate another research study within 30 day precede visit . 10 . Patient medical history hypersensitivity steroids excipients class drug . 11 . Treatment systemic corticosteroid chronic intermittent disorder ( e.g. , dermatitis ) last six month present condition require . 12 . Medical history alcoholism and/or drug abuse last 2 year . 13 . Medical history positive testing HIV , hepatitis B C. 14 . The patient us drug list list page 5 Table .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>rhinitis</keyword>
	<keyword>ciclesonide</keyword>
	<keyword>intermittent rhinitis</keyword>
	<keyword>persistent rhinitis</keyword>
</DOC>